Dendrite's SalesPlus Europe Signs Sanofi-Synthelabo and Bayer Belgium to Three Year Agreements.

MORRISTOWN, N.J.--(BUSINESS WIRE)--July 6, 1999--

Sanofi-Synthelabo Selects Dendrite's SFE Solution for

Belgian Sales Force, Replacing Premier from IMS 

Bayer Belgium Extends Long-Term Relationship With Dendrite 

Dendrite International, Inc. (NASDAQ/NMS:DRTE) today announced that its SalesPlus Europe division has signed three-year licensing agreements with global pharmaceutical companies, Sanofi-Synthelabo, based in Paris, France and Bayer Belgium, based in Leverkusen, Germany.

Daniel Falque, Business Manager of Sanofi-Synthelabo, said, "With the merging of Sanofi and Synthelabo, we became the second largest French pharmaceutical company, and felt we needed a reputable system that could offer us a comprehensive package of proven software and services to support our objectives. SalesPlus effectively met all of our needs."

Noting that SalesPlus Europe was chosen to replace Walsh, Sanofi-Synthelabo`s previous sales force effectiveness provider, Dendrite Chairman and CEO John Bailye said, "SalesPlus will provide Sanofi-Synthelabo with essential tools and capabilities necessary to increase the effectiveness of their sales representatives in today's more competitive market. We are very excited about this relationship and look forward to working with Sanofi-Synthelabo."

Bailye added that Dendrite is also pleased with Bayer Belgium's extension of their licensing agreement with SalesPlus Europe for an additional three years.

Dr Jean-Philippe Milon, Health Care Division Manager of Bayer, said, "Our history with SalesPlus software and support services demonstrated to us the importance of working with an organization that focuses on the vertical pharmaceutical market. SalePlus understands our goals and offers sales force solutions geared toward our specific markets."

ABOUT SANOFI-SYNTHELABO

Sanofi-Synthelabo ranks 2nd amongst pharmaceutical groups in France, 6th in Europe and 18th group worldwide. The Group's core therapeutic areas are Cardiovascular/Thrombosis, Central Nervous System, Oncology and Internal Medicine. Sanofi-Synthelabo would have generated sales of FRF 35 billion in 1998. Sanofi-Synthelabo is present in more than 100 countries and on 5 continents with a total staff of 33,000, including a sales force of 8,750. With R&D expenditure totaling FRF 5.6 billion in 1998, Sanofi-Synthelabo has around 5,000 scientists and support staff working in 15 R&D centers worldwide and has a portfolio of 50 compounds in development.

ABOUT BAYER

Bayer is world renowned for its effective drugs with few side effects. Cardiovascular medication, antibiotics, products for diabetics and a genetically engineered blood coagulation factor for the treatment of hemophilia are only a few prominent examples of the extensive range of Bayer's pharmaceutical products.

Bayer is an international research-based group with major businesses in polymers, chemicals, health care, agriculture, animal health and imaging technologies. With more than 145,000 employees worldwide, the group recorded income before taxes of DM 5.1 billion on sales of DM 55 billion in 1997. Last year, DM 5 billion was earmarked for capital expenditures. A record DM 4.1 billion was budgeted for research and development, attesting to the company's drive for innovation.

ABOUT DENDRITE

As a leading global provider of highly specialized, integrated product and service offerings for the Pharmaceutical and Consumer Package Goods (CPG) industries, Dendrite supports corporate strategies for a sustained competitive advantage. Thousands of sales representatives and their managers from over 150 companies and 17 countries rely on Dendrite for a uniquely tailored combination of tools, information and skills to help them prepare for tomorrow's challenges and improve their sales success. Focusing strongly on outcomes, Dendrite combines its modular software products with specifically tailored coaching and support services. With a global infrastructure as its foundation, Dendrite's commitment to unparalleled service has been the hallmark of the business and the basis of strong customer loyalty since the Company's inception in 1986.

Headquartered in Morristown, New Jersey, Dendrite employs over 1100 people around the world. For more information, visit the Company's Web site at http://www.drte.com.

Note: Dendrite is a registered trademark of Dendrite International, Inc.

This press release may contain statements that, if not verifiable historical fact, may be viewed as forward-looking statements that could predict future events or outcomes with respect to Dendrite and its business. The predictions embodied in these statements will involve risks and uncertainties and, accordingly, Dendrite's actual results may differ significantly from the results discussed or implied in such forward-looking statements.